Roxee Medication Guide

Methylprednisolone Acetate

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Liquid (Suspension) Multiple FDA labelers Official label facts Owner quick guide first

Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts

Reference refreshed

Aug 6, 2026, 7:47 p.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications

FDA application data refreshed

Aug 6, 2026, 7:47 p.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports

Safety data refreshed

Aug 6, 2026, 7:49 p.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details

Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
The reference fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC

Illustration placeholder

Methylprednisolone Acetate

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Liquid (Suspension) Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Methylprednisolone Acetate

Treatment of inflammation and related disorders in dogs; treatment of allergic and dermatologic disorders in dogs; and as supportive therapy to antibacterial treatment of severe infections in dogs. Treatment of inflammation and related disorders in cats; treatment of allergic and dermatologic disorders in cats; and as supportive therapy to antibacterial treatment of severe infections in cats. Treatment of inflammation and related disorders in horses. Species commonly shown: Both, Dog, Restricted During Pregnancy, Horse, Restricted During Pregnancy.

Generic name

Methylprednisolone Acetate

Brand names

Methylprednisolone Acetate Inj., Medrol® Tablets, Depo-Medrol®, Methylprednisolene Tablets

Manufacturer

Multiple FDA labelers

Species

Both, Dog, Horse, Cat

Dosage forms

Liquid (Suspension), Tablet

Prescription

Prescription required

Completeness

100%

Validation

Complete

Brand names

Methylprednisolone Acetate Inj. Medrol® Tablets Depo-Medrol® Methylprednisolene Tablets methylprednisolone Depo-Medrol Medrol

Dosage forms

Liquid (Suspension) Tablet

Indications / Uses

Warnings / Contraindications

Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for use in horses intended for food. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis,

Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for use in horses intended for food. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis,

Side Effects

Top reported reactions (openFDA): Lack of efficacy - NOS, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Anorexia, Weight loss, Diarrhoea.

FAQ

Both, Dog, Restricted During Pregnancy, Horse, Restricted During Pregnancy, Horse, Not For Meat Production, Cat, Restricted During Pregnancy, Restricted During Pregnancy

Yes. Roxee shows this as prescription-only.

Liquid (Suspension), Tablet

Related Conditions

Congestive heart failure Corneal ulcer Diabetes Mellitus Diabetes Mellitus Diabetes Mellitus (Canine) Dystocia Metritis Pain (acute, chronic)

Source Transparency

Verified source: https://www.roxee.ai/meds/
Verified source: https://animaldrugsatfda.fda.gov
Verified source: https://animaldrugsatfda.fda.gov/adafda/views/#/search
Verified source: https://api.fda.gov/animalandveterinary/event.json
Verified source: https://www.roxee.ai/conditions/
Verified source: https://www.accessdata.fda.gov/spl/data/e0f47704-8d7a-4a66-b1cc-7e5b25615852/e0f47704-8d7a-4a66-b1cc-7e5b25615852.xml
Last refreshed: Aug 6, 2026, 7:47 p.m.
Last verified: Feb 12, 2026, 10:44 p.m.
Validation status: Complete

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For use in dogs as an anti-inflammatory agent.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

Not for human use
Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis
Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome
The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids
Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions
Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic
Appropriate antibacterial therapy should be instituted immediately
Not for use in horses intended for food
Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis,
Ear pain (1 reports)
Ear infection NOS (1 reports)
Ear discharge (1 reports)

When to call the vet:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.
Facial swelling or hives.
Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence

Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Methylprednisolone Acetate; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2025-US-074210

Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 26 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2025-US-074210

Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2025-US-074210

Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Ear pain (1 reports), Ear infection NOS (1 reports), Ear discharge (1 reports), Drooling (1 reports), Disorientation (1 reports)

Body systems represented Signal grouping

Digestive (5), Skin & allergy (2), Neurologic (2), Behavior (1)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Cat (18 reports), Dog (14 reports)

Breed metadata in reports Metadata only

Domestic Shorthair (3), ['Crossbred Canine/dog', 'Catahoula Leopard Dog'] (2), ['Chihuahua', 'Dog (unknown)'] (1), Shepherd Dog - German (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Methylprednisolone Acetate fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Not for human use, Clinical and experimental data have demonstrated that corticosteroids administered orally or parente, Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in an, The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predispos, Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindi

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Methylprednisolone Acetate brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.

Vet source depth

openFDA case USA-USFDACVM-2025-US-074210 · adverse_reaction · adverse reactions
Contraindication source · fda_animal_drugs · warnings contraindications
FDA application profile · official_label · quick facts
FDA application profile · official_label · quick facts
Medication usage source · fda_animal_drugs · quick facts
SPL · document · documents
SPL · document · documents
SPL · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 10:44 PM UTC

Sources:

FDA application profile · official_label
FDA application profile · official_label
Medication usage source · fda_animal_drugs
Depo-Medrol® · official_label
openFDA case USA-USFDACVM-2025-US-074210 · adverse_reaction

Safety & side effects

Side effects to monitor:

Not for human use
Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis
Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome
The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids
Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions

Most reported reactions:

Ear pain (1 reports)
Ear infection NOS (1 reports)
Ear discharge (1 reports)

Explore reported case details

Emergency warning signs:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species

Cat, Dog, Horse, Restricted During Pregnancy

Indication / use

For use in dogs as an anti-inflammatory agent.

Form / route / dose

Form: Liquid (Suspension), Tablet
Route: Intramuscular, Intrasynovial, Oral
Confirm product label and patient-specific plan.

Warnings

High: Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and e…

Adverse-event caveat

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both

Manufacturer: Multiple FDA labelers

Form: Liquid (Suspension), Tablet

Identifiers:

NADA: 11403 NADA: 12204 NADA: 135771 NADA: 136212 NDC Package: 54771-1613-1 NDC Package: 54771-1614-1 NDC Package: 54771-3547-1 NDC Package: 69043-042-10 NDC Product: 54771 NDC Product: 69043

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/11403 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/135771 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

High: Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for use in horses intended for food. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis,

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Stored reports

Matching reports

Active filters

Species

Breed

Size / weight

Age

Sex

Seriousness

Outcome

Reaction

Body system

Region

Received after

Received before

Reset

Drill into common report signals

Abnormal cytology (2) Abnormal stool colouration (2) Behavioural disorder NOS (2) Convulsion (2) Other (12) Digestive (6) Neurologic (4) Skin & allergy (4)

Showing up to 50 matching reports.

USA-USFDACVM-2026-US-013230

Received 2026-03-22 · MSK · MSK

Non-serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (5.08 Kilogram)
Age: 1-3 years (2 Year)
Sex: Male Unknown
Region: USA
Reactions: General illnessMedication error NOS
Body systems: Other
Outcomes: Outcome Unknown

USA-USFDACVM-2026-US-011044

Received 2026-03-11 · MSK · MSK

Serious

Species: Dog
Breed: ['Chihuahua', 'Dog (unknown)']
Size / weight: 10-24 lb (4.54 Kilogram)
Age: 4-7 years (7 Year)
Sex: Female Neutered
Region: USA
Reactions: Gastric ulcerMelaenaNeurological disorder NOS
Body systems: OtherNeurologic
Outcomes: Ongoing

USA-USFDACVM-2026-US-011773

Received 2026-03-05 · MSK · MSK

Non-serious

Species: Dog
Breed: Shepherd Dog - German
Size / weight: 50-99 lb (42.184 Kilogram)
Age: 8+ years (8 Year)
Sex: Female Neutered
Region: USA
Reactions: Lack of efficacy (ectoparasite) - flea
Body systems: Effectiveness
Outcomes: Ongoing

USA-USFDACVM-2026-US-008713

Received 2026-02-27 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (5.806 Kilogram)
Age: 8+ years (12 Year)
Sex: Male Neutered
Region: USA
Reactions: WoundPruritusMedication error NOSLack of efficacy - NOSAlopecia localMoist dermatitisEar infection NOSSkin ulcerHead shake - ear disorderItchy earsAbnormal cytologyEar painEar dischargeLocal erythemaDecreased appetiteExudative skin conditionDiscomfort NOS
Body systems: OtherSkin & allergyEffectivenessDigestive
Outcomes: Ongoing

USA-USFDACVM-2026-US-012550

Received 2026-02-21 · MSK · MSK

Serious

Species: Dog
Breed: ['Crossbred Canine/dog', 'Catahoula Leopard Dog']
Size / weight: 50-99 lb (25.129 Kilogram)
Age: 1-3 years (2 Year)
Sex: Male Neutered
Region: USA
Reactions: DroolingJaw disorderSeizure NOSLateral recumbencyStiffness NOSConvulsionDisorientationWobblinessElevated total bilirubinStraining to defecateAbnormal stool colourationPost ictal state
Body systems: DigestiveOtherNeurologic
Outcomes: Ongoing

USA-USFDACVM-2026-US-006927

Received 2026-02-11 · MSK · MSK

Serious

Species: Dog
Breed: ['Crossbred Canine/dog', 'Catahoula Leopard Dog']
Size / weight: 50-99 lb (25.129 Kilogram)
Age: 1-3 years (2 Year)
Sex: Male Neutered
Region: USA
Reactions: DroolingJaw disorderSeizure NOSLateral recumbencyStiffness NOSConvulsionDisorientationWobblinessElevated total bilirubinStraining to defecateAbnormal stool colourationPost ictal state
Body systems: DigestiveOtherNeurologic
Outcomes: Ongoing

USA-USFDACVM-2026-US-007621

Received 2026-01-23 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (5.9 Kilogram)
Age: 4-7 years (5 Year)
Sex: Male Neutered
Region: USA
Reactions: Injection site skin change NOSInjection site alopeciaInjection site weeping (see also Skin)DehiscenceInjection site mucopurulent dischargeInjection site necrosis
Body systems: OtherSkin & allergy
Outcomes: Recovered/Normal

USA-USFDACVM-2026-US-001377

Received 2026-01-12 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Longhair
Size / weight: Under 10 lb (4.064 Kilogram)
Age: 8+ years (15 Year)
Sex: Female Unknown
Region: USA
Reactions: DermatitisSkin ulcerLack of efficacy - NOSAbnormal histology NOSBehavioural disorder NOSVocalisationTachycardiaHigh blood pressureRetinal disorder NOSGranulomaDecreased appetitePain NOSWeight lossAbnormal menace reflex testDilated pupilsLoss of visionSkin irritationInjection site dermatitisElevated blood urea nitrogen (BUN)PacingElevated amylaseHypokalaemiaElevated symmetrical dimethylarginine (SDMA)Vomiting bile
Body systems: OtherEffectivenessBehaviorDigestive
Outcomes: Ongoing

USA-USFDACVM-2025-US-074908

Received 2025-12-16 · MSK · MSK

Non-serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (5.67 Kilogram)
Age: 8+ years (9 Year)
Sex: Female Neutered
Region: USA
Reactions: Diarrhoea
Body systems: Digestive
Outcomes: Ongoing

USA-USFDACVM-2025-US-074210

Received 2025-12-16 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (4.536 Kilogram)
Age: 1-3 years (3 Year)
Sex: Female Unknown
Region: USA
Reactions: Injection site mass NOSAbnormal cytology
Body systems: Other
Outcomes: Ongoing

USA-USFDACVM-2025-US-071202

Received 2025-12-02 · MSK · MSK

Non-serious

Species: Dog
Breed: Catahoula Leopard Dog
Size / weight: 50-99 lb (28.803 Kilogram)
Age: 4-7 years (6 Year)
Sex: Female Neutered
Region: USA
Reactions: Pica NOSDiarrhoeaBloody stoolWeight loss
Body systems: OtherDigestive
Outcomes: Ongoing

USA-USFDACVM-2025-US-070057

Received 2025-11-18 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (5.9 Kilogram)
Age: 4-7 years (5 Year)
Sex: Male Neutered
Region: USA
Reactions: Injection site skin change NOSInjection site alopeciaInjection site weeping (see also Skin)DehiscenceInjection site mucopurulent dischargeInjection site necrosis
Body systems: OtherSkin & allergy
Outcomes: Ongoing

USA-USFDACVM-2025-US-068337

Received 2025-11-17 · MSK · MSK

Non-serious

Species: Dog
Breed: ['Akita', 'Dog (unknown)']
Size / weight: 50-99 lb (37.1 Kilogram)
Age: 4-7 years (6.5 Year)
Sex: Female Neutered
Region: USA
Reactions: Behavioural disorder NOSLethargy (see also Central nervous system depression in Neurological)
Body systems: BehaviorNeurologic
Outcomes: Outcome Unknown

USA-USFDACVM-2025-US-065278

Received 2025-10-27 · MSK · MSK

Serious

Species: Dog
Breed: Beagle
Size / weight: 10-24 lb (10.932 Kilogram)
Age: 4-7 years (4.5 Year)
Sex: Male Neutered
Region: USA
Reactions: Leucopenia NOSNeutropeniaEosinopenia
Body systems: Other
Outcomes: Ongoing

USA-USFDACVM-2025-US-063264

Received 2025-10-17 · MSK · MSK

Non-serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (6.123 Kilogram)
Age: 8+ years (9 Year)
Sex: Female Neutered
Region: USA
Reactions: HyperactivityBiting - pruritus (see also Behavioural disorders)
Body systems: OtherSkin & allergy
Outcomes: Ongoing

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Grouped by Body System

Digestive (5) · Drooling, Diarrhea, Decreased appetite Skin & allergy (2) · Biting - pruritus, Alopecia local Neurologic (2) · Unsteady walking (ataxia), Convulsion Behavior (1) · Behavioral disorder (unspecified) Other (22) · Elevated alanine aminotransferase, Ear pain, Ear infection NOS

Most Reported Reactions

Body system	Cases	Species	Serious cases
Other	1	Cat	1
Other	1	Cat	1
Other	1	Cat	1
Digestive	1	Dog	1
Other	1	Dog	1
Other	1	Cat	1
Other	1	Cat	1
Other	1	Dog	1

Species coverage: Cat (18) Dog (14)

View detailed reaction table

Body system	Species	Seriousness	Frequency	Reports
Neurologic	Cat	Non-serious	-	1
Other	Dog	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Digestive	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Digestive	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Digestive	Cat	Serious	-	1
Other	Dog	Serious	-	1
Neurologic	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Non-serious	-	1
Digestive	Dog	Serious	-	1
Digestive	Dog	Serious	-	1
Skin & allergy	Cat	Non-serious	-	1
Behavior	Cat	Serious	-	1
Other	Cat	Serious	-	1
Skin & allergy	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-074210

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Medrol® Tablets SPL · SPL Methylprednisolene Tablets SPL · SPL Depo-Medrol® SPL · SPL

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

No owner handouts linked yet.

Official label / PI

No official label or package insert links yet.

SPL

FOI

No FOI links yet.

Medrol® Tablets

SPL · SPL

Open original

FDA Structured Product Label

Medrol® Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Zoetis Inc.
NADA: 11403
Status: RX
Form: Tablet
Route: Oral
Species: Dog • Cat

Composition / specifications

Each tablet contains 1 or 4 milligrams of methylprednisolone.

Dogs

Indication

For use in dogs as an anti-inflammatory agent.

Dosage

Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, cushingoid syndrome. The presence of active tuberculosis, diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely in dogs and cats but should be kept in mind. Anti-inflammatory action of corticosteroids may mask signs of infection.

Cats

Indication

For use in cats as an anti-inflammatory agent.

Dosage

5 to 15 pounds, 2 milligrams; 15 to 40 pounds, 2 to 4 milligrams; 40 to 80 pounds, 4 to 8 milligrams.

Limitations

Methylprednisolene Tablets

SPL · SPL

Open original

FDA Structured Product Label

Methylprednisolene Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Cronus Pharma Specialities India Private Ltd.
NADA: 135-771
Status: RX
Form: Tablet
Route: Oral
Species: Dog • Cat

Composition / specifications

Each tablet contains 1, 2 or 4 milligrams of methylprednisolone.

Dogs

Indication

For use as an anti-inflammatory agent.

Dosage

Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. 5 to 15 pounds: 2 milligrams; 15 to 40 pounds: 2 to 4 milligrams; 40 to 80 pounds: 4 to 8 milligrams.

Limitations

Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, cushingoid syndrome. The presence of active tuberculosis diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely but should be kept in mind. Anti-inflammatory action of corticosteroids may mask signs of infection.

Cats

Indication

For use as an anti-inflammatory agent.

Dosage

Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. 5 to 15 pounds: 2 milligrams; 15 to 40 pounds: 2 to 4 milligrams; 40 to 80 pounds: 4 to 8 milligrams.

Limitations

Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, corneal ulcer, and cushingoid syndrome. The presence of diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure, renal insufficiency and active tuberculosis necessitates carefully controlled use. Some of the above conditions occur only rarely in dogs and cats but should be kept in mind. Antiinflammatory action of corticosteroids may mask signs of infection.

Depo-Medrol®

SPL · SPL

Open original

FDA Structured Product Label

Depo-Medrol®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Zoetis Inc.
NADA: 12204
Status: RX
Form: Liquid (Suspension)
Route: Intramuscular, Intrasynovial
Species: Dog • Restricted During Pregnancy • Cat

Composition / specifications

Each milliliter of aqueous suspension contains 20 or 40 milligrams of methylprednisolone acetate.

Dogs

Indication

Treatment of inflammation and related disorders in dogs; treatment of allergic and dermatologic disorders in dogs; and as supportive therapy to antibacterial treatment of severe infections in dogs.

Dosage

2 to 40 milligrams (up to 120 milligrams in extremely large breeds or dogs with severe involvement) intramuscularly. Dosage may be repeated when necessary. Up to 20 milligrams intrasynovially. Dosage may be repeated when necessary.

Limitations

Cats

Indication

Treatment of inflammation and related disorders in cats; treatment of allergic and dermatologic disorders in cats; and as supportive therapy to antibacterial treatment of severe infections in cats.

Dosage

10 to 20 milligrams intramuscularly. Dosage may be repeated when necessary.

Limitations

Horses

Indication

Treatment of inflammation and related disorders in horses.

Dosage

200 milligrams intramuscularly. Dosage may be repeated when necessary. 40 to 240 milligrams intrasynovially. Dosage may be repeated when necessary.

Limitations

Methylprednisolone Acetate Inj.

SPL · SPL

Open original

FDA Structured Product Label

Methylprednisolone Acetate Inj.

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Cronus Pharma Specialities India Private Ltd.
NADA: 136-212
Status: RX
Form: Liquid (Suspension)
Route: Intramuscular, Intrasynovial
Species: Dog • Horse • Cat

Composition / specifications

Each milliliter of aqueous suspension contains 20 or 40 milligrams of methylprednisolone acetate.

Dogs

Indication

Treatment of inflammation and related disorders; treatment of allergic and dermatologic disorders; and as supportive therapy to antibacterial treatment of severe infections.

Dosage

2 to 40 milligrams (up to 120 milligrams in extremely large breeds or dogs with severe involvement) intramuscularly. Dosage may be repeated when necessary. Or up to 20 milligrams intrasynovially. Dosage may be repeated when necessary.

Limitations

Cats

Indication

Treatment of inflammation and related disorders; treatment of allergic and dermatologic disorders; and as supportive therapy to antibacterial treatment of severe infections.

Dosage

10 to 20 milligrams intramuscularly. Dosage may be repeated when necessary.

Limitations

Horses

Indication

Treatment of inflammation and related disorders.

Dosage

200 milligrams intramuscularly. Dosage may be repeated when necessary. Or 40 to 240 milligrams intrasynovially. Dosage may be repeated when necessary.

Limitations

Not for use in horses intended for food. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.

Depo-Medrol SPL

SPL · Structured Product Label

Open original

FDA Structured Product Label XML for Depo-Medrol. Use the source link for the full official labeling record.

Medrol SPL

SPL · Structured Product Label

Open original

FDA Structured Product Label XML for Medrol. Use the source link for the full official labeling record.

methylprednisolone SPL

SPL · Structured Product Label

Open original

FDA Structured Product Label XML for methylprednisolone. Use the source link for the full official labeling record.

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/675/Medrol%C2%AE%20Tablets · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2153/Methylprednisolene%20Tablets · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/703/Depo-Medrol%C2%AE · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/522/Methylprednisolone%20Acetate%20Inj. · document · SPL
https://www.accessdata.fda.gov/spl/data/e0f47704-8d7a-4a66-b1cc-7e5b25615852/e0f47704-8d7a-4a66-b1cc-7e5b25615852.xml · document · Structured Product Label
https://www.accessdata.fda.gov/spl/data/918578dc-39dd-4f8c-bbdf-dc0f51a51c55/918578dc-39dd-4f8c-bbdf-dc0f51a51c55.xml · document · Structured Product Label
https://www.accessdata.fda.gov/spl/data/49596195-c0f0-413f-b49e-a488172cd04b/49596195-c0f0-413f-b49e-a488172cd04b.xml · document · Structured Product Label

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
The reference fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC

Official (FDA)

Identity: Generic ingredient • FDA branded products available

Official FDA brands: Depo-Medrol Medrol methylprednisolone

Manufacturer mapping: Multiple FDA labelers

Case-reported brands (openFDA): MSK

Catalog species: Both • FDA-labeled species: Cat, Dog, Horse, Restricted During Pregnancy

Rx/OTC: RX

Form/route: Liquid (Suspension), Tablet • Intramuscular, Intrasynovial, Oral

Applications: NADA 11403 • NADA 135-771 • NADA 12204 • NADA 136-212

NDC: Packages 54771-1613-1 54771-1614-1 54771-3547-1 69043-042-10 • Products 54771 69043

Documents: • SPL: 4 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 25 • Cat 49 • View

Case summaries: 15 (showing 8) • View

openFDA reports are unverified and do not prove causation.

Explore

Related conditions: Congestive heart failure Corneal ulcer Diabetes Mellitus Diabetes Mellitus Diabetes Mellitus (Canine) Dystocia Metritis Pain (acute, chronic)

Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes

ICD10_CM: E11.9

Type 2 diabetes mellitus without complications

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for use in horses intended for food. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, (Contraindication, High)

Top reaction signals

Ear pain (1) Ear infection NOS (1) Ear discharge (1) Drooling (1) Disorientation (1) Discomfort NOS (1) Dilated pupils (1) Digestive tract hypomotility (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

NADA: 11403 NADA: 12204 NADA: 135771 NADA: 136212 NDC Package: 54771-1613-1 NDC Package: 54771-1614-1 NDC Package: 54771-3547-1 NDC Package: 69043-042-10 NDC Product: 54771 NDC Product: 69043

Package NDC	Product NDC	Status
54771-1613-1	54771	-
54771-1614-1	54771	-
54771-3547-1	54771	-
69043-042-10	69043	-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Depo-Medrol SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Medrol SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
methylprednisolone SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 122 Clinical 1 Manufacturer 0 Marketing 0

Current Field Facts

side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Anorexia, Weight l… (Clinical, 2026-04-11)
contraindications: Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that … (Official, 2026-04-12)
contraindications: Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that … (Official, 2026-04-11)
contraindications: Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that … (Official, 2026-02-12)
manufacturer_name: Multiple FDA labelers (Official, 2026-08-06)
manufacturer_name: Multiple FDA labelers (Official, 2026-08-05)
manufacturer_name: Multiple FDA labelers (Official, 2026-08-04)
manufacturer_name: Multiple FDA labelers (Official, 2026-08-03)
manufacturer_name: Multiple FDA labelers (Official, 2026-08-02)
manufacturer_name: Multiple FDA labelers (Official, 2026-08-01)
manufacturer_name: Multiple FDA labelers (Official, 2026-07-31)
manufacturer_name: Multiple FDA labelers (Official, 2026-07-30)
manufacturer_name: Multiple FDA labelers (Official, 2026-07-29)
manufacturer_name: Multiple FDA labelers (Official, 2026-07-28)
manufacturer_name: Multiple FDA labelers (Official, 2026-07-27)
manufacturer_name: Multiple FDA labelers (Official, 2026-07-26)
manufacturer_name: Multiple FDA labelers (Official, 2026-07-25)
manufacturer_name: Multiple FDA labelers (Official, 2026-07-25)
manufacturer_name: Multiple FDA labelers (Official, 2026-07-22)
manufacturer_name: Multiple FDA labelers (Official, 2026-07-22)

Recent Revisions

side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
Medrol® Tablets RX Methylprednisolone Tablet • Oral Label highlights Official documents	Zoetis Inc.	NADA 11403	Approved	Feb 23, 2024
Methylprednisolene Tablets RX Methylprednisolone Tablet • Oral Label highlights Official documents	Cronus Pharma Specialities India Private Ltd.	NADA 135-771	Approved	Nov 24, 2023
Depo-Medrol® RX Methylprednisolone Acetate Liquid (Suspension) • Intramuscular, Intrasynovial Label highlights Official documents	Zoetis Inc.	NADA 12204	Approved	Dec 7, 2021
Methylprednisolone Acetate Inj. RX Methylprednisolone Acetate Liquid (Suspension) • Intramuscular, Intrasynovial Label highlights Official documents	Cronus Pharma Specialities India Private Ltd.	NADA 136-212	Approved	Feb 1, 2018

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog • Cat

Composition / specifications

Each tablet contains 1 or 4 milligrams of methylprednisolone.

Dogs

Indication

For use in dogs as an anti-inflammatory agent.

Dosage

Limitations

Cats

Indication

For use in cats as an anti-inflammatory agent.

Dosage

5 to 15 pounds, 2 milligrams; 15 to 40 pounds, 2 to 4 milligrams; 40 to 80 pounds, 4 to 8 milligrams.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat

Composition / specifications

Each tablet contains 1, 2 or 4 milligrams of methylprednisolone.

Dogs

Indication

For use as an anti-inflammatory agent.

Dosage

Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. 5 to 15 pounds: 2 milligrams; 15 to 40 pounds: 2 to 4 milligrams; 40 to 80 pounds: 4 to 8 milligrams.

Limitations

Cats

Indication

For use as an anti-inflammatory agent.

Dosage

Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. 5 to 15 pounds: 2 milligrams; 15 to 40 pounds: 2 to 4 milligrams; 40 to 80 pounds: 4 to 8 milligrams.

Limitations

Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, corneal ulcer, and cushingoid syndrome. The presence of diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure, renal insufficiency and active tuberculosis necessitates carefully controlled use. Some of the above conditions occur only rarely in dogs and cats but should be kept in mind. Antiinflammatory action of corticosteroids may mask signs of infection.

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Restricted During Pregnancy • Cat

Composition / specifications

Each milliliter of aqueous suspension contains 20 or 40 milligrams of methylprednisolone acetate.

Dogs

Indication

Treatment of inflammation and related disorders in dogs; treatment of allergic and dermatologic disorders in dogs; and as supportive therapy to antibacterial treatment of severe infections in dogs.

Dosage

Limitations

Cats

Indication

Treatment of inflammation and related disorders in cats; treatment of allergic and dermatologic disorders in cats; and as supportive therapy to antibacterial treatment of severe infections in cats.

Dosage

10 to 20 milligrams intramuscularly. Dosage may be repeated when necessary.

Limitations

Horses

Indication

Treatment of inflammation and related disorders in horses.

Dosage

200 milligrams intramuscularly. Dosage may be repeated when necessary. 40 to 240 milligrams intrasynovially. Dosage may be repeated when necessary.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Horse • Cat

Composition / specifications

Each milliliter of aqueous suspension contains 20 or 40 milligrams of methylprednisolone acetate.

Dogs

Indication

Treatment of inflammation and related disorders; treatment of allergic and dermatologic disorders; and as supportive therapy to antibacterial treatment of severe infections.

Dosage

Limitations

Cats

Indication

Treatment of inflammation and related disorders; treatment of allergic and dermatologic disorders; and as supportive therapy to antibacterial treatment of severe infections.

Dosage

10 to 20 milligrams intramuscularly. Dosage may be repeated when necessary.

Limitations

Horses

Indication

Treatment of inflammation and related disorders.

Dosage

200 milligrams intramuscularly. Dosage may be repeated when necessary. Or 40 to 240 milligrams intrasynovially. Dosage may be repeated when necessary.

Limitations

FDA page: Open in Animal Drugs @ FDA

Usage

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive

Drooling (1) • Dog Diarrhea (1) • Dog Decreased appetite (1) • Cat Bloody diarrhoea (1) • Dog Blood in vomit (1) • Dog

Showing top 5 for Digestive.

Skin & allergy

Biting - pruritus (1) • Cat Alopecia local (1) • Cat

Showing top 5 for Skin & allergy.

Neurologic

Unsteady walking (1) • Cat Convulsion (1) • Dog

Showing top 5 for Neurologic.

Behavior

Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Other

Elevated alanine aminotransferase (1) • Dog Ear pain (1) • Cat Ear infection NOS (1) • Cat Ear discharge (1) • Cat Disorientation (1) • Dog

Show more (17)

Discomfort NOS (1) • Cat Dilated pupils (1) • Cat Digestive tract hypomotility (1) • Dog Diabetes (1) • Dog Dermatitis (1) • Cat Dental calculus (1) • Dog Dehiscence (1) • Cat Cushings disease NOS (1) • Dog Confusion (1) • Dog Bumps on skin (1) • Cat Bloody stool (1) • Dog Atopic allergy NOS (1) • Cat Abnormal stool colouration (1) • Dog Abnormal radiograph finding (1) • Cat Abnormal menace reflex test (1) • Cat Abnormal histology NOS (1) • Cat Abnormal cytology (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Cat, Domestic Shorthair, Male, 2 year, 5.08 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 0.30 mL per animal • Reactions: General illness, Medication error NOS • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2026-US-013230
Serious AE: No
Treated For AE: No
Sex: Male
Age: 2.00 Year
Weight: 5.080 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Suspension
Dose: 0.30 mL per animal

Reactions Reported:

General illness Medication error NOS

Outcomes: Outcome Unknown

Dog, ['Chihuahua', 'Dog (unknown)'], Female, 7 year, 4.54 kilogram • Drug: MSK, Oral, Frequency: 12 per hour • Reactions: Gastric ulcer, Melaena, Neurological disorder NOS • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-011044
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 7.00 Year
Weight: 4.540 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Frequency: 12 per hour

Reactions Reported:

Gastric ulcer Melaena Neurological disorder NOS

Outcomes: Ongoing

Dog, Shepherd Dog - German, Female, 8 year, 42.184 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Lack of efficacy (ectoparasite) - flea • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-011773
Serious AE: No
Treated For AE: No
Sex: Female
Age: 8.00 Year
Weight: 42.184 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Unassigned

Reactions Reported:

Lack of efficacy (ectoparasite) - flea

Outcomes: Ongoing

Cat, Domestic Shorthair, Male, 12 year, 5.806 kilogram • Drug: MSK, Suspension, Intramuscular, Dose: 1 mL per animal • Reactions: Wound, Itching, Medication error NOS, Lack of efficacy - NOS, Alopecia local… • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-008713
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 12.00 Year
Weight: 5.806 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Intramuscular
Form: Suspension
Dose: 1 mL per animal

Reactions Reported:

Wound Itching Medication error NOS Lack of efficacy - NOS Alopecia local Moist dermatitis Ear infection NOS Skin ulcer Head shake - ear disorder Itchy ears Abnormal cytology Ear pain Ear discharge Local erythema Decreased appetite Exudative skin condition Discomfort NOS

Outcomes: Ongoing

Dog, ['Crossbred Canine/dog', 'Catahoula Leopard Dog'], Male, 2 year, 25.129 kilogram • Drug: MSK, Injection, solution, Subcutaneous • Reactions: Drooling, Jaw disorder, Seizure NOS, Lateral recumbency, Stiffness NOS… • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-012550
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 2.00 Year
Weight: 25.129 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Injection, solution

Reactions Reported:

Drooling Jaw disorder Seizure NOS Lateral recumbency Stiffness NOS Convulsion Disorientation Wobbliness Elevated total bilirubin Straining to defecate Abnormal stool colouration Post ictal state

Outcomes: Ongoing

Dog, ['Crossbred Canine/dog', 'Catahoula Leopard Dog'], Male, 2 year, 25.129 kilogram • Drug: MSK, Injection, Subcutaneous • Reactions: Drooling, Jaw disorder, Seizure NOS, Lateral recumbency, Stiffness NOS… • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-006927
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 2.00 Year
Weight: 25.129 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Injection

Reactions Reported:

Drooling Jaw disorder Seizure NOS Lateral recumbency Stiffness NOS Convulsion Disorientation Wobbliness Elevated total bilirubin Straining to defecate Abnormal stool colouration Post ictal state

Outcomes: Ongoing

Cat, Domestic Shorthair, Male, 5 year, 5.9 kilogram • Drug: MSK, Suspension, Unknown • Reactions: Injection site skin change NOS, Injection site alopecia, Injection site weeping, Dehiscence, Injection site mucopurulent discharge… • Outcome: Recovered/Normal

Report ID: USA-USFDACVM-2026-US-007621
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 5.00 Year
Weight: 5.900 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Suspension

Reactions Reported:

Injection site skin change NOS Injection site alopecia Injection site weeping Dehiscence Injection site mucopurulent discharge Injection site necrosis

Outcomes: Recovered/Normal

Cat, Domestic Longhair, Female, 15 year, 4.064 kilogram • Drug: MSK, Suspension, Subcutaneous • Reactions: Dermatitis, Skin ulcer, Lack of efficacy - NOS, Abnormal histology NOS, Behavioral disorder (unspecified)… • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-001377
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 15.00 Year
Weight: 4.064 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Suspension

Reactions Reported:

Dermatitis Skin ulcer Lack of efficacy - NOS Abnormal histology NOS Behavioral disorder (unspecified) Vocalisation Tachycardia High blood pressure Retinal disorder NOS Granuloma Decreased appetite Pain NOS Weight loss Abnormal menace reflex test Dilated pupils Loss of vision Skin irritation Injection site dermatitis Elevated blood urea nitrogen Pacing Elevated amylase Hypokalaemia Elevated symmetrical dimethylarginine Vomiting bile

Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on Roxee are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Methylprednisolone Acetate

Data freshness

Methylprednisolone Acetate

Medication Snapshot

Methylprednisolone Acetate

Indications / Uses

Warnings / Contraindications

Side Effects

FAQ

What species is this commonly shown for?

Does this usually require a prescription?

What dosage forms are listed?

Related Conditions

Source Transparency

Add to My Pet's Medications

Pet Owner Quick Guide

Next actions

Medication Research Insights

What to know

Evidence tension

Reaction signal map

Species and breed lens

What your vet may verify

What to watch next

Evidence

Vet Fast Scan

Quick Facts

Warnings / Contraindications

Adverse Reactions

Reported case explorer

USA-USFDACVM-2026-US-013230

USA-USFDACVM-2026-US-011044

USA-USFDACVM-2026-US-011773

USA-USFDACVM-2026-US-008713

USA-USFDACVM-2026-US-012550

USA-USFDACVM-2026-US-006927

USA-USFDACVM-2026-US-007621

USA-USFDACVM-2026-US-001377

USA-USFDACVM-2025-US-074908

USA-USFDACVM-2025-US-074210

USA-USFDACVM-2025-US-071202

USA-USFDACVM-2025-US-070057

USA-USFDACVM-2025-US-068337

USA-USFDACVM-2025-US-065278

USA-USFDACVM-2025-US-063264

Grouped by Body System

Most Reported Reactions

Source Documents

Owner handouts

Official label / PI

SPL

FOI

Medrol® Tablets

Medrol® Tablets

Dogs

Cats

Methylprednisolene Tablets

Methylprednisolene Tablets

Dogs

Cats

Depo-Medrol®

Depo-Medrol®

Dogs

Cats

Horses

Methylprednisolone Acetate Inj.

Methylprednisolone Acetate Inj.

Dogs

Cats

Horses

Depo-Medrol SPL

Medrol SPL

methylprednisolone SPL

At a Glance

Counseling and Monitoring Highlights

Identifiers & Packages

Enriched Documents

Data Sources & Change Log

FDA Products & Applications (Animal Drugs @ FDA)

What It's For (FDA Label Highlights)